» Articles » PMID: 35749444

Fatigue in Incident Peritoneal Dialysis and Mortality: A Real-world Side-by-side Study in Brazil and the United States

Abstract

Background: We tested if fatigue in incident Peritoneal Dialysis associated with an increased risk for mortality, independently from main confounders.

Methods: We conducted a side-by-side study from two of incident PD patients in Brazil and the United States. We used the same code to independently analyze data in both countries during 2004 to 2011. We included data from adults who completed KDQOL-SF vitality subscale within 90 days after starting PD. Vitality score was categorized in four groups: >50 (high vitality), ≥40 to ≤50 (moderate vitality), >35 to <40 (moderate fatigue), ≤35 (high fatigue; reference group). In each country's cohort, we built four distinct models to estimate the associations between vitality (exposure) and all-cause mortality (outcome): (i) Cox regression model; (ii) competing risk model accounting for technique failure events; (iii) multilevel survival model of clinic-level clusters; (iv) multivariate regression model with smoothing splines treating vitality as a continuous measure. Analyses were adjusted for age, comorbidities, PD modality, hemoglobin, and albumin. A mixed-effects meta-analysis was used to pool hazard ratios (HRs) from both cohorts to model mortality risk for each 10-unit increase in vitality.

Results: We used data from 4,285 PD patients (Brazil n = 1,388 and United States n = 2,897). Model estimates showed lower vitality levels within 90 days of starting PD were associated with a higher risk of mortality, which was consistent in Brazil and the United States cohorts. In the multivariate survival model, each 10-unit increase in vitality score was associated with lower risk of all-cause mortality in both cohorts (Brazil HR = 0.79 [95%CI 0.70 to 0.90] and United States HR = 0.90 [95%CI 0.88 to 0.93], pooled HR = 0.86 [95%CI 0.75 to 0.98]). Results for all models provided consistent effect estimates.

Conclusions: Among patients in Brazil and the United States, lower vitality score in the initial months of PD was independently associated with all-cause mortality.

Citing Articles

Exploring symptom clusters in Chinese patients with peritoneal dialysis: a network analysis.

Duan D, Zhou X, Yan Y, Li Y, Hu Y, Li Q Ren Fail. 2024; 46(1):2349121.

PMID: 38916144 PMC: 11207921. DOI: 10.1080/0886022X.2024.2349121.


Prevalence and influencing factors of fatigue among patients undergoing continuous ambulatory peritoneal dialysis: A cross-sectional study.

Maninet S, Nakrit B, Suttavat P Belitung Nurs J. 2023; 9(4):391-398.

PMID: 37645579 PMC: 10461161. DOI: 10.33546/bnj.2715.


Fatigue in incident peritoneal dialysis and mortality: A real-world side-by-side study in Brazil and the United States.

Guedes M, Wallim L, Guetter C, Jiao Y, Rigodon V, Mysayphonh C PLoS One. 2022; 17(6):e0270214.

PMID: 35749444 PMC: 9231740. DOI: 10.1371/journal.pone.0270214.

References
1.
Rayner H, Zepel L, Fuller D, Morgenstern H, Karaboyas A, Culleton B . Recovery time, quality of life, and mortality in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2014; 64(1):86-94. PMC: 4069238. DOI: 10.1053/j.ajkd.2014.01.014. View

2.
Jhamb M, Weisbord S, Steel J, Unruh M . Fatigue in patients receiving maintenance dialysis: a review of definitions, measures, and contributing factors. Am J Kidney Dis. 2008; 52(2):353-65. PMC: 2582327. DOI: 10.1053/j.ajkd.2008.05.005. View

3.
Davey C, Webel A, Sehgal A, Voss J, Huml A . Fatigue in Individuals with End Stage Renal Disease. Nephrol Nurs J. 2019; 46(5):497-508. PMC: 7047987. View

4.
Morton R, Sellars M . From Patient-Centered to Person-Centered Care for Kidney Diseases. Clin J Am Soc Nephrol. 2019; 14(4):623-625. PMC: 6450337. DOI: 10.2215/CJN.10380818. View

5.
van Sandwijk M, Al Arashi D, van de Hare F, van der Torren J, Kersten M, Bijlsma J . Fatigue, anxiety, depression and quality of life in kidney transplant recipients, haemodialysis patients, patients with a haematological malignancy and healthy controls. Nephrol Dial Transplant. 2018; 34(5):833-838. DOI: 10.1093/ndt/gfy103. View